Research Advance of Chinese Medicine in Treating Atherosclerosis: Focus on Lipoprotein-Associated Phospholipase A2

被引：2

作者：

Wang, Lu-ming ^{[1
]}

Zhang, Wen-lan ^{[1
]}

Lyu, Nuan ^{[1
]}

Suo, Yan-rong ^{[2
]}

Yang, Lin ^{[1
]}

Yu, Bin ^{[3
]}

Jiang, Xi-juan ^{[1
]}

机构：

[1] Tianjin Univ Tradit Chinese Med, Sch Integrat Med, Tianjin 301617, Peoples R China

[2] Ganzhou Peoples Hosp, Dept Tradit Chinese Med, Ganzhou 341000, Jiangxi, Peoples R China

[3] Tianjin Univ Tradit Chinese Med, Sch Med Technol, Tianjin 301617, Peoples R China

来源：

CHINESE JOURNAL OF INTEGRATIVE MEDICINE | 2024年 / 30卷 / 03期

基金：

中国国家自然科学基金;

关键词：

lipoprotein-associated phospholipase A2; atherosclerosis; inflammation; oxidative stress; apoptosis; Chinese medicine; PLATELET-ACTIVATING-FACTOR; OXYGEN SPECIES PRODUCTION; RHO-KINASE; MACROPHAGE APOPTOSIS; A(2) EXPRESSION; LYSOPHOSPHATIDYLCHOLINE; RESVERATROL; INFLAMMATION; INHIBITION; LP-PLA(2);

D O I：

10.1007/s11655-023-3611-6

中图分类号：

R [医药、卫生];

学科分类号：

10 ;

摘要：

As a serious cardiovascular disease, atherosclerosis (AS) causes chronic inflammation and oxidative stress in the body and poses a threat to human health. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a member of the phospholipase A2 (PLA2) family, and its elevated levels have been shown to contribute to AS. Lp-PLA2 is closely related to a variety of lipoproteins, and its role in promoting inflammatory responses and oxidative stress in AS is mainly achieved by hydrolyzing oxidized phosphatidylcholine (oxPC) to produce lysophosphatidylcholine (lysoPC). Moreover, macrophage apoptosis within plaque is promoted by localized Lp-PLA2 which also promotes plaque instability. This paper reviews those researches of Chinese medicine in treating AS via reducing Lp-PLA2 levels to guide future experimental studies and clinical applications related to AS.

引用

页码：277 / 288

页数：12

共 50 条

[21] Expression and purification of lipoprotein-associated phospholipase A2,a key enzyme involved in atherosclerosis
Fu-jun ZHANG~(2
4 Graduate School of the Chinese Academy of Sciences.Chinese Academy of Sciences
Acta Pharmacologica Sinica, 2006, (06) : 679 - 684
[22] Lipoprotein-associated phospholipase A2 and risk of stroke
Gorelick, Philip B.
AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (12A): : 34F - 40F
[23] Clinical Role of Lipoprotein-Associated Phospholipase A2
Miklishanskaya, S. V.
Lyakishev, A. A.
Kukharchuk, V. V.
KARDIOLOGIYA, 2013, 53 (03) : 59 - 70
[24] Lipoprotein-associated phospholipase A2 structure and function
Gonzalez, Tara
Bahnson, Brian
FASEB JOURNAL, 2014, 28 (01):
[25] An evolving story of lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular risk prediction
Macphee, CH
Nelson, JJ
EUROPEAN HEART JOURNAL, 2005, 26 (02) : 107 - 109
[26] Association between the Lipoprotein-Associated Phospholipase A2 Activity and the Progression of Subclinical Atherosclerosis
Liu, Jing
Wang, Wei
Qi, Yue
Yong, Qiang
Zhou, Guanghua
Wang, Miao
Sun, Jiayi
Liu, Jun
Jia, Zhangrong
Zhao, Dong
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2014, 21 (06) : 532 - 542
[27] Expression and purification of lipoprotein-associated phospholipase A2, a key enzyme involved in atherosclerosis
Zhang, Fu-Jun
Cai, Mao-Jun
Shen, Jing-Kang
Wang, Yi-Ping
ACTA PHARMACOLOGICA SINICA, 2006, 27 (06) : 679 - 684
[28] Lipoprotein-Associated Phospholipase A2 Activity Predicts Progression of Subclinical Coronary Atherosclerosis
Kinney, Gregory L.
Snell-Bergeon, Janet K.
Maahs, David M.
Eckel, Robert H.
Ehrlich, James
Rewers, Marian
Hokanson, John E.
DIABETES TECHNOLOGY & THERAPEUTICS, 2011, 13 (03) : 381 - 387
[29] Orally active inhibitors of lipoprotein-associated phospholipase A2 for the potential treatment of atherosclerosis
Tranter, D
DRUG DISCOVERY TODAY, 2001, 6 (06) : 324 - 324
[30] Expression and purification of lipoprotein-associated phospholipase A2, a key enzyme involved in atherosclerosis
Fu-jun Zhang
Mao-jun Cai
Jing-kang Shen
Yi-ping Wang
Acta Pharmacologica Sinica, 2006, 27 : 679 - 684

← 1 2 3 4 5 →